Loading data for IRD — first visit, this takes a few seconds.
Opus Genetics Inc. (IRD)
NasdaqCM: IRD
· Real-Time Price · USD
3.85
+0.16 (4.34%)
At close: Aug 19, 2026, 10:40 AM
Opus Genetics Inc. (IRD) Stock Price, Analysis & Data
4.34% (1D)
| Bid | 2.63 |
| Market Cap | 335.7M |
| Revenue (ttm) | 9.86M |
| Net Income (ttm) | -107.61M |
| Beta | 0.58 |
| EPS (ttm) | -1.29 |
| PE Ratio (ttm) | n/a |
| Forward PE | -5.69 |
| P/B (ttm) | -25.70 |
| P/S (ttm) | 34.06 |
| Earnings Date | Nov 11, 2026 |
| Ask | 4.62 |
| Volume | 188,044 |
| Avg. Volume (20D) | 938,769 |
| Open | 3.76 |
| Previous Close | 3.69 |
| Day's Range | 3.76 - 3.91 |
| 52-Week Range | 1.11 - 5.81 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About IRD
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It develops OPGx-LCA5, an early-onset retinal degeneration that is in Phase 1/2 clinical trial for the treatment of LCA5-associated IRD; and OPGx-BEST1 to treat BEST1-associated retinal disease. The compa...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 10, 2005
Employees 27
Stock Exchange NasdaqCM
Ticker Symbol IRD
Website https://opusgtx.com
Financial Performance
In 2025, Opus Genetics's revenue was 14.2M, an increase of 29.15% compared to the previous year's 10.99M. Earnings were -49.59M, a decrease of -13.8%.
Financial StatementsEarnings Surprise
Opus Genetics has released their quarterly earnings on Aug 6, 2026:
Opus Genetics Inc. is scheduled to release its earnings on Nov 11, 2026, before market opens.
Analysts project revenue of ... Upgrade
Analysts project revenue of ... Upgrade
Page 1 of 2